Patient access

Eligible, but Unable to Attend: The Trial Schedule as an Access Barrier

Review travel, time away from work, caregiving and reimbursement timing as practical barriers to clinical trial participation.

By Lampgen Clinical Research

An appointment card, transit ticket and child backpack on a kitchen table, representing practical participation demands.
Conceptual editorial illustration; it does not depict an observed study procedure, actual patient data or a demonstrated treatment outcome.

3 min read · estimated

Sources
Clinical eligibilityPractical participation
A hypothetical planning exercise; support availability varies by trial.

What the source reported

NCI explains that participation can involve travel, lodging, meals, parking and child or elder care costs. It advises patients to ask which expenses the study or other support sources may cover. [1] ICH E8(R1) identifies stakeholder input and operational feasibility as important to study design. [2] Neither source establishes that a patient who meets eligibility criteria can absorb the time and cash demands of a particular schedule.

What this means for trial teams

Lampgen’s analysis: practical access begins before the first completed visit. A patient may be clinically eligible and interested, yet unable to leave work, arrange care or pay for transport in advance. Those questions belong in feasibility and participant-support planning, with no assumptions about an individual’s resources or willingness.

Try a one-cycle walkthrough. List the required in-person appointments, collection visits and follow-up contacts using the protocol. Add realistic travel and waiting time with input from local sites and patients. Identify where visits must remain separate and where the approved design allows coordination. Do not describe a hypothetical timetable as the schedule for an actual study.

Then examine timing of support. Reimbursement after a visit may still require a person to have cash beforehand. Ask which costs are eligible, what documentation is required, how requests are submitted and when payment is expected. Confirm the actual program before telling participants help is available. Clear information also includes any expenses that remain their responsibility.

Consider a hypothetical participant who needs two separate weekday visits and must arrange both transport and childcare. Even if a study covers some travel expenses, the timing, documentation and lost work may still affect whether attendance is possible. This example illustrates questions to ask; it does not estimate the burden experienced by a study population.

Language and digital access can shape the same pathway. A support process that is understandable only through a complicated portal may be difficult to use. Teams should work within approved arrangements to explain options in a suitable format and direct questions to the right contact. Collect only the personal information needed for that process, with the applicable privacy protections.

For protocol planners, bring patient and site input early enough to influence practical choices. For active studies, document recurring logistical concerns and route proposals through the appropriate study governance. Any visit changes must retain scientific purpose, participant protection and required approvals. A well-intended local workaround can create new problems if it bypasses the protocol.

The significance for representation is concrete: access should be evaluated along the participation pathway, not assumed from a recruitment message. Where data collection is appropriate, examine reasons for declining, missed visits and support use with meaningful context. Those measures need careful interpretation because financial strain or caregiving may not be disclosed.

Lampgen recommends including participant logistics in the assignment brief for clinical operations support. The work is to make options and responsibilities clear, identify recurrent barriers and coordinate decisions. Recruitment expands opportunity only when people can reasonably act on the invitation.

Sources

  1. NCI — Who Pays for Clinical Trials?
  2. ICH — E8(R1), General Considerations for Clinical Studies

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?